StockNews.AI
HIMS
StockNews.AI
56 days

Kirby McInerney LLP Announces Investigation Against Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

1. Kirby McInerney LLP is investigating Hims & Hers for potential securities violations. 2. Novo Nordisk terminated its partnership with Hims & Hers due to deceptive marketing. 3. Hims & Hers shares fell 34% following the partnership termination announcement. 4. Investigation indicates possible unlawful business practices linked to Hims & Hers. 5. Clients may seek recovery if they purchased Hims & Hers securities recently.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The partnership termination severely impacts HIMS's revenue stream, reminiscent of past reductions affecting similar companies. A substantial drop in stock price reflects significant investor concern.

How important is it?

Legal troubles and loss of key partnerships directly undermine trust and operational capacity, which are critical for HIMS’s stock price stability.

Why Short Term?

The immediate effect of the partnership loss is detrimental. Subsequent legal investigations will keep stock pressure high, affecting short-term investor sentiment dramatically.

Related Companies

NVO
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). The investigation concerns whether Hims & Hers and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” through which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy. On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers shares declined $22.25 per share, or approximately 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025. If you purchased or otherwise acquired Hims & Hers securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out the form below to discuss your rights or interests with respect to these matters without any cost to you. [CONTACT US] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. ContactsKirby McInerney LLPThomas W. Elrod, Esq.212-699-1180https://www.kmllp.cominvestigations@kmllp.com

Related News